Regeneron (REGN +1.7%) gets a lift today as Goldman reiterates its Buy recommendation and raises its price target on the shares to $215 from $196 citing relative YTD underperformance versus the Nasdaq Biotech index and a strong Eylea launch.
Sent to 6,868 people who get email alerts on REGN.
Get email alerts on REGN »
Want to be faster and smarter on all your stocks?
Upgrade all your basic real-time alerts to PRO Alerts, for $30.